Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for impaired awareness of hypoglycemia in type 1 diabetes
NL-OMON48616Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in diabetes mellitus type 1 (T1D), sponsored by Radboud University Medical Center. Primary endpoint: Symptom score in response to the hyperinsulinemic hypoglycemic glucose clamp experiment. Started Nov 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON48616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48616.